...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection
【24h】

Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection

机译:入选并新发现HPV感染的女性按年龄分层的5年子宫颈癌风险

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

It is unclear whether a woman's age influences her risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) upon detection of HPV. A large change in risk as women age would influence vaccination and screening policies. Among 972,029 women age 30-64 undergoing screening with Pap and HPV testing (Hybrid Capture 2, Qiagen, Germantown, MD) at Kaiser Permanente Northern California (KPNC), we calculated age-specific 5-year CIN3+ risks among women with HPV infections detected at enrollment, and among women with newly detected HPV infections at their second screening visit. Women (57,899, 6.0%) had an enrollment HPV infection. Among the women testing HPV negative at enrollment with a second screening visit, 16,724 (3.3%) had a newly detected HPV infection at their second visit. Both enrollment and newly detected HPV rates declined with age (p<0.001). Women with enrollment versus newly detected HPV infection had higher 5-year CIN3+ risks: 8.5% versus 3.9%, (p<0.0001). Risks did not increase with age but declined slightly from 30-34 years to 60-64 years: 9.4% versus 7.4% (p = 0.017) for enrollment HPV and 5.1% versus 3.5% (p = 0.014) for newly detected HPV. Among women age 30-64 in an established screening program, women with newly detected HPV infections were at lower risk than women with enrollment infections, suggesting reduced benefit vaccinating women at older ages. Although the rates of HPV infection declined dramatically with age, the subsequent CIN3+ risks associated with HPV infection declined only slightly. The CIN3+ risks among older women are sufficiently elevated to warrant continued screening through age 65.
机译:目前尚不清楚妇女的年龄是否会影响到检测到HPV时宫颈上皮内瘤变3级或更严重(CIN3 +)的风险。随着年龄的增长,风险的巨大变化将影响疫苗接种和筛查政策。在972029名30-64岁年龄段的30-64岁女性中,他们接受了北加州Kaiser Permanente(KPNC)的Pap和HPV检测(Hybrid Capture 2,Qiagen,Germantown,MD)的筛查,我们计算了检测到的HPV感染女性的5年龄CIN3 +风险在入组时,以及在第二次筛查访视中新发现HPV感染的女性中。女性(57,899,6.0%)感染了HPV。在第二次筛查就诊时HPV阴性的女性中,有16,724(3.3%)人在第二次筛查中新发现了HPV感染。入组率和新发现的HPV率均随年龄下降(p <0.001)。入组患者与新发现的HPV感染女性相比,其5年CIN3 +风险更高:8.5%对3.9%(p <0.0001)。风险并未随着年龄的增长而增加,但从30-34岁降至60-64岁略有下降:HPV入组的风险分别为9.4%和7.4%(p = 0.017),新检测到的HPV为5.1%与3.5%(p = 0.014)。在既定的筛查计划中,年龄在30-64岁之间的妇女中,新发现HPV感染的妇女的风险低于招募感染的妇女,这表明对年龄较大的妇女进行疫苗接种的收益降低。尽管HPV感染率随年龄急剧下降,但随后与HPV感染相关的CIN3 +风险仅略有下降。老年妇女的CIN3 +风险已充分升高,可以继续筛查直至65岁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号